orizon Therapeutics Plc (Horizon Therapeutics) focuses on identifying, developing, acquiring, and commercializing medicines that address unmet medical needs in arthritis, pain, and inflammatory diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The R&D efforts of company focus on new and improved pharma and medicine-based innovations. It strives to develop solutions that improve yield and overall profitability. It emphasizes on therapy areas including rare diseases, autoimmune diseases and severe inflammatory diseases. The pipeline comprises over 20 programs. In 2022, we disclosed the commencement of five clinical trials and anticipate initiating several additional trials in 2023. This includes a scheduled Phase 3 program for dazodalibep in Sjogren’s syndrome. In January 2023, the initiation of our Phase 2 trial for daxdilimab in discoid lupus erythematosus, or DLE, was announced. It operates offices in Canada, Europe, the United States and Japan. The company spent US$437.9 million on R&D in FY2022, which as a percentage of revenue stood at 12.1%.